Abstract
To the Editor: Rohaan et al. (Dec. 8 issue)1 report that in patients with advanced melanoma, progression-free survival was longer with tumor-infiltrating lymphocyte (TIL) therapy than with ipilimumab. However, they did not discuss the clinical implications of huge disparities in overall survival between men and women, with a hazard ratio for death of 0.52 (favoring TIL therapy) in men and 1.58 (favoring ipilimumab therapy) in women (Fig. S9 in the Supplementary Appendix of their article, available at NEJM.org). Sex-specific differences in melanoma incidence and mortality have long been recognized and were found to persist in a contemporary patient cohort.2,3 In .
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
